Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

May 06, 2020

Source URL: https://qa1.novartis.us/news/media-releases/novartis-announces-fda-approval-met-inhibitor-tabrectatm-metastatic-non-small-cell-lung-cancer-metex14-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-announces-fda-approval-met-inhibitor-tabrectatm-metastatic-non-small-cell-lung-cancer-metex14-0